2013 - CTS 2013 Congress


This page contains exclusive content for the member of the following sections: TTS, CTS. Log in to view.

Oral Communications 7

15.4 - Isolation and Characterization of Multipotent Cells from Human Fetal Dermis

Presenter: Cinzia, Chinnici, Palermo, Italy
Authors: Cinzia Chinnici1,2,3,4,5, Giandomenico Amico1,2,3,4,5, Marcello Monti1,2,3,4,5, Stefania Motta1,2,3,4,5, Marco Spada1,2,3,4,5, Jorg C Gerlach1,2,3,4,5, Bruno Gridelli1,2,3,4,5, Pier Giulio Conaldi1,2,3,4,5

Isolation and Characterization of Multipotent Cells from Human Fetal Dermis

Cinzia Chinnici1,2,3,4,5, Giandomenico Amico1,2,3,4,5, Marcello Monti1,2,3,4,5, Stefania Motta1,2,3,4,5, Marco Spada1,2,3,4,5, Jorg C Gerlach1,2,3,4,5, Bruno Gridelli1,2,3,4,5, Pier Giulio Conaldi1,2,3,4,5

1Regenerative Medicine and Biomedical Technology Unit, Fondazione Ri.MED, Palermo, Italy; 2Translational Medicine, Istituto Clinico Humanitas, University of Milan, Rozzano, Italy; 3Department of Surgery, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT) , Palermo, Italy; 4Department of Surgery and Bioengineering, McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, United States; 5Department of Laboratory Medicine and Advanced Biotechnologies, Mediterranean Institute for Transplantation and Advanced Specialized Therapies (ISMETT) , Palermo, Italy

The use of human fetal cells may have interesting applications in Regenerative Medicine. Particularly, the fetal tissue is expected to contain a larger number of “immature” cells than the adult tissue, without posing the ethical dilemmas of the embryonic tissue. We report that cells from human fetal dermis, termed multipotent fetal dermal cells (MFDCs), can be isolated with high efficiency by using a non-enzymatic, cell outgrowth method. The employed isolation method is rapid and simple, does not require a purification step, and it is easily reproducible. Moreover, it yields a quite homogeneous cell population which could be expanded up to 28 passages under standard culture conditions. The expanded cell population have features of mesenchymal stromal cells. MFDCs were plastic-adherent, had fibroblastic appearance, were >90% CD90, CD105, and CD73-positive, and negative for hematopoietic markers CD34, CD14, CD45, and for HLA-DR. Moreover, MFDCs exhibited osteo-, adipo- and chondrogenic differentiation capacities. As MFDCs proliferate extensively, with no loss of the multilineage differentiation potential up to passage 25, they may be an ideal source for cell therapy to repair damaged tissues and organs. In addition, MFDCs were not recognized as targets by lymphocyte T in vitro, thus supporting their feasibility for allogenic transplantation. Moreover, the expansion protocol did not affect the normal phenotype and karyotype of the cells evaluated by classic cytogenetic analysis. When compared with adult dermal cells, fetal cells displayed several advantages, including a greater cellular yield after isolation, the ability to proliferate longer, and the retention of differentiation potential. Interestingly, MFDCs exhibited the pluripotency marker SSEA4 (90.56 ± 3.15% fetal vs. 10.5 ± 8.5% adult), and co-expressed mesenchymal and epithelial markers (>80% CD90+/CK18+ cells), suggesting a broad potency and a predisposition toward the epithelial differentiation of fetal dermal cells. MFDCs differentiated into epithelial-like cells after DMSO treatment, and were also able to form capillary structures in an angiogenesis assay.
In conclusion,the most interesting aspect of our study is the fact that multipotent cells can be successful isolated from small fetal skin biopsies and maintained in culture for long periods, with retention of multipotency, stability and low immunogenicity, thus generating large quantities of cells and supporting their feasibility in clinical settings. Possible applications of MFDCs could concern tissue engineering for bone reconstruction. If we could obtain bone tissue starting from a small skin biopsy this would dramatically facilitate the use of tissue engineering methods. Given the promising results, the future perspective is to translate the concept of MFDCs as cells of therapeutic interest into experimental models of tissue regeneration.
 

 

 


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada